The study will assess the duration of protection of single doses of 2 different long acting muscarinic antagonists against methacholine induced bronchoconstriction.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
13
long acting muscarinic antagonist
long acting muscarinic antagonist
inhaler device used to deliver active tiotropium or placebo
Asthma Research Lab
Saskatoon, Saskatchewan, Canada
Change from baseline methacholine bronchoprotection at 96 hours
assessed by dose shift of geometric mean methacholine PC20 data
Time frame: pre treatment versus 96 hour post treatment
Change from baseline methacholine bronchoprotection at 1 hour
assessed by dose shift of geometric mean methacholine PC20 data
Time frame: pre treatment versus 1 hour post treatment
Change from baseline methacholine bronchoprotection at 24 hours
assessed by dose shift of geometric mean methacholine PC20 data
Time frame: pre treatment versus 24 hours post treatment
Change from baseline methacholine bronchoprotection at 48 hours
assessed by dose shift of geometric mean methacholine PC20 data
Time frame: pre treatment versus 48 hours post treatment
Change from baseline methacholine bronchoprotection at 72 hours
assessed by dose shift of geometric mean methacholine PC20 data
Time frame: pre treatment versus 72 hours post treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
inhaler device used to deliver active glycopyrronium or placebo